MARKHAM, ON, Aug. 13 /CNW/ - Cytochroma Inc. announced today that Joel Z.
Melnick, MD has joined Cytochroma's management team as Vice President,
Clinical & Regulatory Affairs. Dr. Melnick will be responsible for managing
the clinical development of Cytochroma's new Vitamin D therapies and for
obtaining marketing approvals from the United States Food and Drug
Administration (FDA) and Canada's Therapeutic Products Directorate (TPD).
Dr. Melnick was previously Senior Medical Director in the Global
Pharmaceutical Research and Development Group at Abbott Laboratories (North
Chicago, IL). There, he managed clinical trials, regulatory submissions,
marketing approvals and post-launch support for Zemplar(R) (paricalcitol)
Capsules and Injection, currently one of the world's leading Vitamin D hormone
replacement therapies for secondary hyperparathyroidism (SHPT) in chronic
kidney disease (CKD).
"We are delighted to announce the hiring of Dr. Melnick," said Charles W.
Bishop, PhD, President and CEO. "He will greatly boost our ability to rapidly
develop and launch products targeting CKD patients. We expect, through Dr.
Melnick's leadership and proven expertise, to submit New Drug Applications to
the FDA for three new Vitamin D products within the next two years."
Dr. Melnick completed his medical degree, internship, and residency in
internal medicine and pediatrics at Creighton University, and completed a
post-doctoral fellowship in pediatric and adult nephrology at the University
of Texas Southwestern Medical Center. Dr. Melnick subsequently served as
Assistant Professor of Pediatrics at Northwestern University, where he
conducted research in metabolism and cardio-renal disease.
"Cytochroma has built a deep product pipeline targeting CKD,
interactively working with the many leading experts on Vitamin D therapeutics
and nephrology who comprise its Scientific Advisory Board. I look forward to
working with such prominent and talented key opinion leaders," stated Dr.
"With the addition of Dr. Melnick, Cytochroma has significantly increased
the breadth and depth of its in-house Vitamin D product development
expertise." stated Alan J. Lewis, PhD, Chairman of the Board. "Cytochroma now
counts among the senior management team the key individuals responsible for
developing and commercializing Hectorol(R) and Zemplar(R), two products which
dominate the US$600+ million market for Vitamin D hormone replacement
therapies in North America."
About Cytochroma Inc.
Cytochroma (www.cytochroma.com) is a specialty pharmaceutical company
engaged in the development and commercialization of proprietary products to
treat and prevent the clinical consequences of Vitamin D insufficiency. The
Company has an advanced portfolio of new therapies for Vitamin D insufficiency
and secondary hyperparathyroidism associated with CKD. In addition, the
Company is developing novel therapies to treat hyperproliferative disorders,
such as cancer and psoriasis, and hyperphosphatemia.
For further information:
For further information: Eric J. Messner, Vice President, Commercial
Operations, (905) 479-5306 ext. 338, email@example.com